Additionally, inhibition of the ERK/Mnk1/eIF4E by this agent enhances dasatinib sensitivity in chronic myeloid leukemia (CML) (Liu et al. 2016). This evidence concerns the gene MAPK1 and chronic myelogenous leukemia, BCR-ABL1 positive.